LivaNova's Vagus Nerve Stimulator Earns CE Mark For Treating Depression
LivaNova announced its vagus nerve stimulator for depression earned the CE mark and said that marketing efforts will be limited in the EU and US.
You may also be interested in...
Special arrangements are needed for VNS for treatment-resistant depression and DBS of the anterior thalamus for refractory epilepsy.
As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.
LivaNova's RECOVER trial will randomize about 1,000 patients with treatment-resistant depression to either LivaNova’s vagus nerve stimulation therapy or a sham therapy and follow them for at least a year.